The hypoglycemic action of glyburide is due to stimulation of pancreatic islet cells, which results in an increase in insulin secretion. Sulfonylureas are believed to bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, thereby reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin. The drug is not effective in the absence of functioning beta-cells, as occurs in diabetes mellitus type 1, or when the number of viable beta-cells is low, as occurs in severe cases of diabetes mellitus type 2.
Prolonged administration of glyburide also produces extrapancreatic effects that contribute to its hypoglycemic activity. These effects include reduction of basal hepatic glucose production and an enhanced peripheral sensitivity to insulin secondary to an increase in insulin receptors or to changes in the events that follow insulin-receptor binding. The relative importance of each of these actions to the overall therapeutic effect of the drug will vary among oral antidiabetic agents and from patient to patient, which may account for the variability in potency among these drugs. Like glipizide, glyburide exhibits mild diuretic actions but does not affect uric acid concentrations.
Heavy consumption of the essential amino acid lysine (as indicated in the treatment of cold sores) has allegedly shown false positives in some and was cited by American shotputter C. J. Hunter as the reason for his positive test, though in 2004 he admitted to a federal grand jury that he had injected nandrolone.  A possible cause of incorrect urine test results is the presence of metabolites from other AAS, though modern urinalysis can usually determine the exact AAS used by analyzing the ratio of the two remaining nandrolone metabolites. As a result of the numerous overturned verdicts, the testing procedure was reviewed by UK Sport . On October 5, 2007, three-time Olympic gold medalist for track and field Marion Jones admitted to use of the drug, and was sentenced to six months in jail for lying to a federal grand jury in 2000. 
===Name of drug=== *Will be capitalized if it is a trade name (brand name) or uncapitalized if it is a generic name. *Two trade names that are nearly identical (eg Adalat PA and Adalat XL) need not have separate entries unless there is a particular reason for doing so. *Names will be listed alphabetically and broken into an appropriate number of pages (with 200-500??? items per page) Peg-Intron is the correct spelling that you have listed as Pegetron for pegylated interferaon alfa2b made by schering plough and marketed in the US for HCV